CLINICAL_TRIALS
trial_result
· 2022-06-10
Clinical Trial Update: Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer [Phase 2]
Summary
Phase 2 trial evaluating pembrolizumab with or without CC-486 in platinum-resistant ovarian cancer was terminated; results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Translational Research in Oncology | Conditions: Epithelial Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-06-10